Imaging non-dopaminergic function in Parkinson's disease

Molecular Imaging and Biology

Volumn 9, Issue 4, 2007, Pages 217-222

  Brooks, David J ^a,b  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Acetylcholine; Microglia; Noradrenaline; Parkinson's disease; Positron emission tomography; Serotonin

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 3 (2 AZETIDINYLMETHOXY)PYRIDINE; 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; BENZOVESAMICOL I 123; DIPRENORPHINE C 11; DOPA; FLUORODEOXYGLUCOSE F 18; FLUORODOPA F 18; IODINE 123; L 829165; L 829165 F 18; METAHYDROXYEPHEDRINE C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE C 11; N METHYLPIPERIDIN 4 YL PROPIONATE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; NEUROPROTECTIVE AGENT; TRACER; UNCLASSIFIED DRUG;

CELL ACTIVATION; CELL LOSS; CHOLINERGIC SYSTEM; DIAGNOSTIC IMAGING; DOPAMINERGIC SYSTEM; HUMAN; MICROGLIA; NERVE DEGENERATION; NORADRENERGIC SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

DIAGNOSTIC IMAGING; HUMANS; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 34447103706     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0084-5     Document Type: Review

References (35)

1. Jellinger K. 1987 The pathology of parkinsonism In: Marsden CD, Fahn S (eds) Movement disorders 2 London: Butterworths 124-165
2. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) The accuracy of the clinical diagnosis of Parkinson's disease: A clinicopathological study of 100 cases J Neurol Neurosurg Psychiatry 55:181-184
3. Litvan I, Macintyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J. Mckee A, Brandel JP, Chaudhuri KR, Lai EC, D'olhaberriague L, Pearce RKB, Agid Y. (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies. Arch Neurol 55:969-978, Jul
4. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65:1863-1872
5. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for. HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 1285-1291
6. Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y (2003) Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains. Acta Neuropathol (Berl) 106 518-526
7. Lamarre Y. 1984 Animal models of tremor In: Findley LJ, Capildeo R (eds) Movement disorders: Tremor. London: MacMillan Press 183-194
8. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. Neurology 60:601-605
9. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ (2003) Tremor in Parkinson's disease and serotonergic dysfunction: An (11)C-WAY 100635 PET study. Neurology 60:601-605
10. Mayberg HS, Starkstein SE, Sadzot B, Preziosi T, Andrezejewski PL, Dannals RF, Wagner HN, Jr, Robinson RG (1990) Selective hypometabolism in the inferior frontal lobe in depressed patients with Parkinson's disease. Ann Neurol 28:57-64
11. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY (2003) Serotonin transporters in the midbrain of Parkinson's disease patients: A study with 123I-beta-CIT SPECT. J Nucl Med 44:870-876
12. Becker G, Berg D, Lesch KP, Becker T (2001) Basal limbic system alteration in major depression: A hypothesis supported by transcranial sonography and MRI findings. Int J Neuropsychopharmacol 4:21-31
13. Berg D, Supprian T, Hofmann E, Zeiler B, Jager A, Lange KW, Reiners K, Becker T, Becker G (1999) Depression in Parkinson's disease: Brainstem midline alteration on transcranial sonography and magnetic resonance imaging. J Neurol 246:1186-1193
14. Ding YS, Lin KS, Logan J, Benveniste H, Carter P (2005) Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine. J Neurochem 94:337-351
15. Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, Shea C, Xu Y, King P (2003) Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 50:345-352
16. Remy P, Doder M, Lees AJ, Turjanski N, Brooks DJ (2005) Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain 128:1314-1322
17. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40:399-410
18. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T (1998) Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: A positron emission tomographic study. J Neurol Neurosurg Psychiatry 65:155-163
19. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: An in vivo positron emission tomographic study. Arch Neurol 60:1745-1748
20. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis CA, Davis JG, Moore RY, Dekosky ST (2005) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 253:242-247
21. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T (2005) Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57:168-175
22. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ (2006) In vivo imaging of microglial activation with [(11)C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 21:404-412
23. Jolkkonen J, Jenner P, Marsden CD (1995) l-dopa reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol Brain Res 32:297-307
24. Jones AK, Watabe H, Cunningham VJ, Jones T (2004) Cerebral decreases in opioid receptor binding in patients with central neuropathic pain measured by [11C]diprenorphine binding and PET. Eur J Pain 8:479-485
25. Piccini P, Weeks RA, Brooks DJ (1997) Opioid receptor binding in Parkinson's patients with and without levodopa-induced dyskinesias. Ann Neurol 42:720-726
26. Whone AL, Rabiner EA, Arahata Y, Luthra SK, Hargreaves R, Brooks DJ (2002) Reduced substance P binding in Parkinson's disease complicated by dyskinesias: An F-18-L829165 PET study. Neurology 58:A488-A489
27. Yoshita M (2000) Cardiac uptake of [123I]MIBG separates PD from multiple system atrophy. Neurology 54:1877-1878
28. Druschky A, Hilz MJ, Platsch G, Radespiel-Troger M, Druschky K, Kuwert T, Neundorfer B (2000) Differentiation of Parkinson's disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT. J Neurol Sci 175:3-12
29. Reinhardt MJ, Jungling FD, Krause TM, Braune S (2000) Scintigraphic differentiation between two forms of primary dysautonomia early after onset of autonomic dysfunction: Value of cardiac and pulmonary iodine-123 MIBG uptake. Eur J Nucl Med 27:595-600
30. Courbon F, Brefel-Courbon C, Thalamas C, Alibelli MJ, Berry I, Montastruc JL, Rascol O, Senard JM (2003) Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson's disease. Mov Disord 18:890-897
31. Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, Takashima H, Tsujihata M (1999) Loss of 123I-MIBG uptake by the heart in Parkinson's disease: Assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 40:371-375
32. Yoshita M (1998) Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60-67
33. Yoshita M (1998) Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 155:60-67
34. Hirayama M, Hakusui S, Koike Y, Ito K, Kato T, Ikeda M, Hasegawa Y, Takahashi A (1995) A scintigraphical qualitative analysis of peripheral vascular sympathetic function with meta-[123I]iodobenzylguanidine in neurological patients with autonomic failure. J Auton Nerv Syst 53:230-234
35. Berding G, Schrader CH, Peschel T, van den Hoff J, Kolbe H, Meyer GJ, Dengler R, Knapp WH (2003) [N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 30:127-131